PAIYY Aesthetic Medical International Holdings Group Ltd IFRS Annual reports only
Services-Specialty Outpatient Facilities, NEC · OTC · SEC CIK 1757143 · Reporting currency CNY · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CNY | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 755.67M | 682.59M | 670.09M | 645.59M | 901.57M |
| Cost of revenue | 417.88M | 360.54M | 314.50M | 376.09M | 356.80M |
| Gross profit | 337.79M | 322.05M | 355.59M | 269.50M | 544.78M |
| SG&A expense | 100.78M | 138.60M | 150.38M | 206.97M | 230.65M |
| Interest expense | 8.72M | 14.47M | 21.64M | 27.23M | 29.19M |
| Pretax income | -1.35M | -55.06M | -94.17M | -681.31M | -259.49M |
| Income tax | 23.73M | -15.14M | -18.07M | -11.80M | -12.59M |
| Net income | -19.95M | -37.43M | -76.25M | -586.62M | -235.48M |
| EPS (basic) | -0.14 | -0.28 | -0.93 | -8.89 | -3.61 |
| EPS (diluted) | -0.14 | -0.28 | -0.93 | -8.89 | -3.61 |
| Weighted avg. shares (diluted) | 143.50M | 131.66M | 81.91M | 65.96M | 65.30M |
| Balance sheet | |||||
| Cash & equivalents | 42.84M | 62.34M | 12.16M | 39.29M | 44.38M |
| Receivables | 18.38M | 21.66M | 25.89M | 7.77M | 14.32M |
| Inventory | 14.91M | 15.58M | 27.85M | 30.57M | 33.34M |
| Current assets | — | — | — | — | 206.16M |
| PP&E, netmay include right-of-use assets (IFRS) | 266.24M | 304.22M | 320.82M | 358.75M | 531.94M |
| Total assets | 486.22M | 560.66M | 546.37M | 576.94M | 1.04B |
| Current liabilities | 402.04M | 411.38M | 543.84M | 541.66M | 301.69M |
| Short-term debt | 72.22M | 73.93M | 172.77M | 156.21M | 135.81M |
| Long-term debt | 13.72M | 31.41M | 29.11M | 77.61M | 75.93M |
| Total debt | 85.94M | 105.34M | 201.88M | 233.81M | 211.75M |
| Total liabilities | 476.88M | 527.03M | 672.25M | 763.36M | 612.35M |
| Shareholders' equity | 30.46M | 48.89M | -113.66M | -156.67M | 390.90M |
| Net debt | 43.10M | 43.01M | 189.72M | 194.53M | 167.36M |
| Cash flow statement | |||||
| Operating cash flow | 79.67M | 74.29M | -75.13M | 51.09M | -843,000 |
| Capital expenditure | 30.60M | 55.24M | 1.60M | 33.24M | 38.35M |
| Free cash flow | 49.07M | 19.04M | -76.72M | 17.85M | -39.20M |
| Investing cash flow | -30.32M | -52.25M | 3.11M | -11.53M | -127.37M |
| Financing cash flow | -68.55M | 29.06M | 45.55M | -45.23M | 17.70M |
| Depreciation & amortization | 65.96M | 65.90M | 61.48M | 99.14M | 106.41M |
| Stock-based compensation | 0 | 7.51M | 27.53M | 35.46M | 78.97M |
| Share buybacks | 2.02M | — | — | — | 1.98M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CNY, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.